Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Cosmet Dermatol ; 19(4): 964-969, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31436378

ABSTRACT

BACKGROUND: The outcomes of most therapeutic modalities for recurrent aphthous ulcer (RAU) are still unsatisfactory. AIM: To evaluate lactic acid 5% mouth wash vs Kenalog in Orabase for treatment and prophylaxis of RAU. PATIENTS/METHODS: Forty cases with early-onset idiopathic RAU were enrolled in this study. Patients were divided into two equal groups; group A patients had used Kenalog in Orabase twice daily, and group B patients had used lactic acid 5% mouth wash 3 times daily. All patients had used the therapy for 1-2 weeks according to patients' clinical response that was evaluated according to oral clinical manifestations index (OCMI); before therapy, during course of treatments and in follow-up visits. RESULTS: At the ends of both first and second weeks, from beginning of therapy, OCMI was reduced more in group B patients than in group A with statistically significant results. These results revealed that group B achieved more reduction in the size, pain, and healing time of RAU. During the follow-up period, group A showed 40% recurrence rate while group B showed 5% only. CONCLUSIONS: Lactic acid 5% mouth wash is natural, safe, and effective so it is better alternative to corticosteroids for treatment and prophylaxis of RAU without any side effects.


Subject(s)
Carboxymethylcellulose Sodium/analogs & derivatives , Lactic Acid/administration & dosage , Mouthwashes/administration & dosage , Stomatitis, Aphthous/drug therapy , Triamcinolone Acetonide/administration & dosage , Adult , Carboxymethylcellulose Sodium/administration & dosage , Carboxymethylcellulose Sodium/adverse effects , Drug Administration Schedule , Drug Combinations , Female , Follow-Up Studies , Humans , Lactic Acid/adverse effects , Male , Middle Aged , Mouthwashes/adverse effects , Recurrence , Severity of Illness Index , Stomatitis, Aphthous/diagnosis , Stomatitis, Aphthous/prevention & control , Treatment Outcome , Triamcinolone Acetonide/adverse effects , Young Adult
2.
Dermatol Ther ; 32(5): e13010, 2019 09.
Article in English | MEDLINE | ID: mdl-31237076

ABSTRACT

Alopecia areata (AA) is a chronic inflammatory, recurrent, tissue-specific autoimmune disease, mediated by autoreactive CD8+ T cells, occurring in genetically predisposed individuals. Targeting intrabulbar and peribulbar lymphocytic infiltrate by using squaric acid dibutyl ester and diphenylcyclopropenone (DPCP) in contact immunotherapy is by far the best chemotherapy for AA. The aim of this work was to evaluate the efficacy and safety of combination therapy with DPCP and anthralin in chronic extensive AA. A total of 24 patients (12 were treated only with DPCP and 12 with DPCP and anthralin for at least 24 weeks) were evaluated. Complete hair regrowth was observed in 62.5 and 18.2% of the patients who received DPCP and combination therapy, respectively (p = .04). Hair regrowth duration was different in both groups. The DPCP therapy is superior to the combination therapy with DPCP and anthralin in terms of efficacy, the time of onset of hair regrowth, and the time of completion of hair regrowth, Moreover, combination therapy has more side effects in combination therapy group have been discussed in this work.


Subject(s)
Alopecia Areata/drug therapy , Anthralin/administration & dosage , Cyclopropanes/administration & dosage , Hair/growth & development , Administration, Topical , Adolescent , Adult , Alopecia Areata/diagnosis , Child , Child, Preschool , Chronic Disease , Dermatologic Agents/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Hair/drug effects , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young Adult
3.
Dermatol Surg ; 44(5): 697-704, 2018 May.
Article in English | MEDLINE | ID: mdl-29701622

ABSTRACT

BACKGROUND: Striae distensae (SD) are dermal scars associated with atrophy of the epidermis. OBJECTIVE: To evaluate the effect and safety of intralesional injection of platelet-rich plasma (PRP) versus topical tretinoin 0.05% in treatment of SD. METHODS: Thirty patients (27 females and 3 males) had bilateral striae distensae were enrolled in this study. In every patient, half of the selected striae were treated with PRP intralesional injection. The other half was treated by topical tretinoin. Skin biopsies were taken from both sides before and after the treatment. Digital photographs were taken at the baseline and at the end of follow-up period. Clinical improvement was evaluated by 2 blind dermatologists in addition to the patient's satisfaction rating. RESULTS: There was statistically significant improvement in the SD treated with PRP and topical tretinoin cream. The improvement was more in the SD treated with PRP injections (p = .015). Patient's satisfaction showed that the improvement was more in the PRP-treated side (p = .003). Collagen and elastic fibers in the dermis were increased in all biopsies after treatment. CONCLUSION: PRP injection and topical tretinoin are safe for the treatment of SD, but PRP is more effective and it gives better therapeutic response than tretinoin.


Subject(s)
Dermatologic Agents/administration & dosage , Keratolytic Agents/administration & dosage , Patient Satisfaction , Platelet-Rich Plasma , Striae Distensae/therapy , Tretinoin/administration & dosage , Abdomen/pathology , Administration, Cutaneous , Adolescent , Adult , Female , Humans , Injections, Intralesional/methods , Male , Middle Aged , Striae Distensae/pathology , Thigh/pathology , Time Factors , Treatment Outcome , Video Recording
SELECTION OF CITATIONS
SEARCH DETAIL
...